広報あぐい　2016年5月15日号

Q E Q T a k Q Q Q T Q =

i 415 q q q q Q E Q T a k Q Q Q T Q = 10 30 j 19 25 22 E 23 R 9 i i V 25 60 1 20 1 18 59R1416R30 3018 1211931 30025R 10T1T 425R 11 50 101233 162 633315 22E1011 10T q 26T10T 12 3030 12 12 24 100 1E20 62

kouhou_honbun_20_35_201402.pdf

Ｑ＆Ａ（最終版）.PDF

Microsoft Word - ランチョンプレゼンテーション詳細.doc

PS1-1-1 PS1-1-2 PS1-1-3 PS1-1-4 PS1-1-5 PS1-1-6 PS1-1-7 PS1-1-8 PS1-1-9 1 25 12:4514:18 25 12:4513:15 B PS1-1-10 PS1-2-1 PS1-2-2 PS1-2-3 PS1-2-4 PS1-2-5 PS1-2-6 25 13:1513:36 B PS1-2-7 PS1-3-1 PS1-3-2

C H N

広報あぐい　2015年4月1日号

Microsoft Word - 表紙資料２－４

(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)

食事編_表1_4_0508

untitled

1 3 2 4 3 4 4 4 5 5 6 6 1 7 2 7 3 9 4 9 1 11 2 11 3 11 4 12 5 13 6 17 7 17 8 17 1 18 2 18 3 18 4 19 5 20 6 21 7 21 8 21 1 22 2 25 3 31 2 3 4 5 2004 4 1 6 7 8 9 10 11 12 13 / Gas Assist Injection 14 15

6 1873 6 6 6 2

140 2012 12 12 140 140 140 140 140 1 6 1873 6 6 6 2 3 4 6 6 19 10 39 5 140 7 262 24 6 50 140 7 13 =1880 8 40 9 108 31 7 1904 20 140 30 10 39 =1906 3 =1914 11 6 12 20 1945.3.10 16 1941 71 13 B29 10 14 14

I

I II 1 2 3 4 5 6 7 8 9 10 11 Rp.1) 50mg 3 3 14 Rp.2) 2.5mg 2 14 Rp.1) 2.5mg 3 2 2:1 14 Rp.) 15g 1 3 28 Rp.2) 50 600mg 1 2 28 12 Rp.1) CR 20mg 1 1 1 14 Rp.2) R 200 1 2 14 Rp.3) 3 1 3 14 Rp.1) 2.5mg 0.4

T1 T2 T3 T4-3- -4- -5- 11 11 12 12 12-6- -7- -8- -9- L 12-10- T T T T -11- 12 T1 T2 T3 T4 14 15 16 10 11 12 1 2 10 40 10 45 10 50 4 11 25 11 35 17 18 19 20 21 2.5cm T1 T2 T3 T4 T5 T6 T7 T8 22 23 24 25

437“ƒ

et al., et al., et al., et al., et al., et al., 2 et al., et al., et al., Lancet Pharmacol Res. et al. Jpn J Cancer Res. et al. Jpn J Cancer Res. et al. Tohoku J Exp Med. et al. Jpn Circ J. et al. Cancer

1 ---------------------------------------------------------------------------- 1 ------------------------------------------------------------------------- 2 -------------------------------------------------------------------

サポートブック

untitled

-- -- -3- % % % 6% % % 9 66 95 96 35 9 6 6 9 9 5 77 6 6 5 3 9 5 9 9 55 6 5 9 5 59 () 3 5 6 7 5 7 5 5 6 6 7 77 69 39 3 6 3 7 % % % 6% % % (: ) 6 65 79 7 3 36 33 9 9 5 6 7 3 5 3 -- 3 5 6 76 7 77 3 9 6 5

第５回東京都廃棄物審議会

西食堂

フィジカルコンディショニング

PowerPoint プレゼンテーション

支援リスト3／30.xls

untitled

NO. 2007 10 10 34 10 10 0570-058-669 http://www.i-nouryoku.com/index.html (40 ) () 1 NO. 2007 10 10 2.2 2.2 130 70 20 80 30 () () 9 10 () 78 8 9 () 2 NO. 2007 10 10 4 7 3 NO. 2007 10 10 40 20 50 2 4 NO.

CRA3689A

AVIC-DRZ90 AVIC-DRZ80 2 3 4 5 66 7 88 9 10 10 10 11 12 13 14 15 1 1 0 OPEN ANGLE REMOTE WIDE SET UP AVIC-DRZ90 SOURCE OFF AV CONTROL MIC 2 16 17 1 2 0 0 1 AVIC-DRZ90 2 3 4 OPEN ANGLE REMOTE SOURCE OFF

GJG160842_O.QXD

NPO () NPO -1 - 3 2-2 - 3 500m 3-1-1 500m 600m/s 500m 431 500m FDEL (1999) 500m (2003) 1km 500m 250m 500m (2002) 0.1% 3-1-1 15.7% 3-1-1 24.9% 3-1-2 1000 7.9 7.3 7.3 4 8.5 0.1% 7.25 0.1 7.2 15.7 7.0 10.8

untitled

1. Web21 2001 4 2. Web21 2001 4 3. Web21 2001 4 4. Web21 2001 4 5. BCS Web21 2001 6 6. Web21 2001 6 7. Web21 2001 8 8. - Web21 2001 10 9. 9-1. Web21 2001 10 9-2. d Web21 2001 12 9-3. Web21 2001 12 1. T

…h…L…–…†…fi…g1

RY RO RR RW LN LM LB LC MH MG MB RD RM RG LD CW SB VR BB EB PW PY PP PG PB 0 contents WR LR MR BR DR PM SM MC CB BO 0 P P7 P P5 P9 P 0 P4 P48 P54 P60 P66 P 04 RY RO RR RW RD RM RG LN LM LB LC LD MH MG

高圧・特別高圧限流ヒューズ

L, LS, PL LLLLL LS PLPL 7 I t 9 7 PF T, M,, 0 700 h s s 0.. 7 0 T M M In In Is Is T M... s0 s,000 s 700.00s0 7 0 0. 00 0. 7 k T T.. T 0 T 7. 7. L. 0 T 0 0 T 0 0 0 T 0 0 T 0 0 7 T 0 0. 7 T 0 0 T 7 0 0

近畿中国四国農業研究センター研究報告　第７号

230 C B A D E 50m 558 0 1km (mg L 1 ) T N NO 2 3 N NH 4 N 2.0 0 (a) 2001 1.5 6 20 21 5 1.0 0.5 0.0 2.0 1.5 1.0 0.5 0.0 14:00 17:00 (b) 2001 7 3 4 20:00 23:00 2:00 (h) 5:00 8:00 11:00 10 0 5 10 15

腎不全-第22回.indd

,717=Z 8,04r,s00 I 191,500 3,634,5101 slo 3oo Fl x (+E s954,\+ ElEr2s,, \) *+Errslfir+Errfrl Ir* , \v -il- )v )\2Fif- lv ./l: tt/tv^ Y7 /v7 ,7,v^,/tv YT tv^ 4a tv7 >rtv7 1D s3.so] * E r-il-2f..--_

h4_1_et

1 RY RO RM RG RR RW RD LN LM LB LC LD MW MG MB CW SB VR BB EB WR LR MR BR DR PM SM MC CB BO 2 3 RY RO RR RW RD RM RG LN LM LB LC LD MW MG MB 4 CW SB VR BB EB 5 PI PY PP PG PB 6 WR LR MR BR DR 7 SM MC CB

.N...[..7...doc

1 2 3 STEP1 4 STEP2 STEP3 5 6 7 8 9 1 Solution of Solution of Solution of Solution of Solution of Solution of Solution of Solution of Solution of Solution of Solution of Solution of Solution of Solution

薬局におけるインシデント事例の集計･分析結果

13 11 14 31 13 11 14 31 13 11 14 31 10 13 13 e-mail 18 4,000 13 14 H13.4.1 11.17 11.18 H14.3.31 13 14 31-1- 600 400 (18.4 17.7 17.0 16.0 15.2 8.2 1.0 2 11 10 12 15 3 1015203040 69.5 7.8 22.7 4 (42.5) 34.3

cable_nyuko_070605.indd

Solution Now Solution Now 01 Solution Now 02 Solution Now 03 Solution Now 04 Solution Now Solution Now 01 Solution Now 02 Solution Now 03 Solution Now 04 Solution Now Solution

H01.eps

12-7 12-7 12-7 12-7 12-8 12-10 12-10 12-10 12-11 12-12 12-12 12-14 12-15 12-17 12-18 10 12-19 12-20 12-20 12-21 12-22 12-22 12-23 12-25 12-26 12-26 12-29 12-30 12-30 12-31 12-33 12-34 12-3 12-35 12-36

HR01-1_①準備編_QR73251A.indb

2009 Aida et al. Caries Res 2006;40 2000 100 % 78.7 88.0 96.6 98.8 98.8 98.8 100.0 100.0 100 75 69.4 50 75.3 74.8 73.3 73.1 73.0 72.4 71.8 71.7 51.7 40.2 69.4 68.8 73.6 25 22.3 32.8 21.9 22.9 22.1

がん患者の終末期ケアにおける通所リハビリテーションの役割　介護保険によるがん終末期ケアの可能性

2 3 3 6 7 49 53 13 61 22 27 65 68 34 47 71 73 4 5 7 6 8 9 10 11 12 13 14 15 44 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4

/i 1,,._ /\YF*r$-/t, /.:/ lrfi-/l ty)t- /:V-fi-)v '+l'y)t * /;v--t:--l.'>l la- ' i>rtv /iv-i.-,v /r/tv /, / 'v1 -;l- /v F;:*#(2) A^*f *#(3) t45.5i *7v>/tvz

T75 T55 T45 T67 T54 D81 D71 D51 D61 D41 T95 V83 V73 V63 L93 D81 D71 D51 D61 D41 T95 RX82 V83 V73 V63 L93

T75 T55 T45 T67 T54 D81 D71 D51 D61 D41 T95 V83 V73 V63 L93 D81 D71 D51 D61 D41 T95 RX82 V83 V73 V63 L93 T95 T95T75 T75T5 T55T4 T45T6 T67T54 T54 L93 L93V83 V83V73 V73V63 V63 RX82 RX82N72 N72N61 N61N51

No ( FAX ) (

13-1 03-3862-9111 ( FAX03-3862- ) 9140 13-2 03-3219-8080 13-3 03-3293-1711 250 13-4 03-3292-2051 1-8 8111 13-5 8 11 28 ( 8 111 03-3261-5511 2 18 41 9 91 15 41 15 41 47 13-6 47 9 4 4 03-5343-5611 F 47 47

(1.2) T D = 0 T = D = 30 kn 1.2 (1.4) 2F W = 0 F = W/2 = 300 kn/2 = 150 kn 1.3 (1.9) R = W 1 + W 2 = = 1100 N. (1.9) W 2 b W 1 a = 0

1 1 1.1 1.) T D = T = D = kn 1. 1.4) F W = F = W/ = kn/ = 15 kn 1. 1.9) R = W 1 + W = 6 + 5 = 11 N. 1.9) W b W 1 a = a = W /W 1 )b = 5/6) = 5 cm 1.4 AB AC P 1, P x, y x, y y x 1.4.) P sin 6 + P 1 sin 45

EL 9.5m EL -4.5m ,13Cr, 27 (1978) 292 P.64 B ,, ,, 40 (1991) 453 P.58 2-65SUS316 P.31 H.Ishii, et al, The Effects of Heat Treatments on Corrosion Fatigue Properties of 13%

シンポジウム　報告書_5.PDF

... 2... 2... 2... 2... 2... 3... 3... 4... 6... 6... 6... 10... 10... 13... 13... 15... 17... 18... 21... 22 23... 23... 23... 24... 28... 30... 32 1 2 2 30 3 4 5 6 biodiversity 7 4 8 9 TV 10 NHK 11 12

小川／小川

p TRE p Mp p p M p S p p Tp M p p p p p p p p M T T T p p MT MR MR M M p p M M p p M T T T T T T T T S T M p M p T p M E M M p p p p TT T T p p p T T p T T T T T T T p p pt T T T p S T S S T p T T T T

橡アロマセラピー症状別処方例.PDF

1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20

P0681-P0758-›ºflÅŠpB5.qxd

000/000 Series 000 (VVQ) 000 000 ø ø (VVQ) J C Z 7 F P J G T L S M 68 68 J C Z 7 00 0 00 0 000 68 F P J 000 G T L 68 Series A M 000 S 68 J C Z 7 0 ø 0 ø ø ø ø ø ø ø ø ø ø ø ø ø 0 0 øø øø 686 J C Z 7 687

スライド 1

1 2 3 4 53.6% 38.8% 10.0% 5 6 7 8 9 10 140,000 125,700 119,100100 116,700 115,700 120,000 110,600 105,600 107,600 105,400 100,000 80,000 60,000 40,000 20,000 0 90,400 91,600 58,800 783,00 55,300 52,300

/3'yt trg- tr-i,tgetfr t a )uj nv i > 7 a,/ - tt'2 tt ) > &le ta)vjaai>e&re ii'rd ) )v7ht>jse+>&-^' )L , E1,{9t - )V) tr c t>&r.^+ tv tuv=rt^r.z .1t, 't1nt4 't="td

小川／小川

p TB T T T T TT TT TT M p pp p p M p M p T M p M p p Mp T p Tp M p p Mp M p M p M p M p p T p p T p p T p M p M p M p M p T ptp p M p p p M p p M p Tp Tp p p pp p T T Tp Tp p T p T p T p T p T p T p Mp

L

-G -VG -G -VG.MPa..MPa.1MPa..MPa 1.5MPa 1.5MPa 1.5MPa 1.5MPa 1 s 5 5 - -V 1.51MPa 1.5MPa s s..mpa.mpa 1.5MPa 1.5MPa - -V 1 s s 5 5 1 JISg/H 1. 1.5. 11 SLLBFFB SLLBFTC CCCCBTC..MPa 1.5MPa SLLBFFB CCCCBTC

NJW4108 IC ( ) NJW4108 1cell/2cell IC NJW4108V / Bi-CMOS NJW4108V : SSOP20 P-CHG 1 20 Q-CHG NFB 2 19 CS1 CNT 3 18 CS2 GND 4 17 VS NC 5 16 VREF F-CHG 6

IC ( ) 1cell/2cell IC V / Bi-CMOS V : SSOP20 P-CHG 1 20 Q-CHG NFB 2 19 CS1 CNT 3 18 CS2 GND 4 17 VS NC 5 16 VREF F-CHG 6 15 V + 7 14 TDET 8 13 TH C1 9 12 TL C2 10 11 V - 1 - (Ta=25 C) V + +15 V C1 V C1

橡kaikei_QA_2001_05_11.PDF

3- {a-[(^9)-2-hydroxy-3'(2-morpholirocarbonylamino) ethylaminolprnpoxy I phenylpropionate monohydrnchloride (!s/ml) a m El t) >1! 0 (mllmin) CR/F Cmax (rrolml) p=0.0008 4OOmg l5orngiln X li3oomg

_;-TIL._ I J --' ) /'. (t -/. a rlr. l 111!' Ir': i " b "It'_1_; -1r-_.-- I'!f' I :;(: 1 '1' 1 ' 't'l] S I) I "' :h "'t t-1-i ' J ilt'tt't 1 Jf(i - 7J_.1 _ f F FT'II 1 ' ft - JI '- ll i" ': "'1l li l!

産衛誌57-4たより.indb

A89 26 7 1 9 4 33 1 87 A90 24 A91 23 ACOH2014 A92 4 1 2 3 4 5 6 7 A93 A94 A95 A96 A97 A98 A99 A100 A101 27 8 1 9 A102 4 33 A103 A104 26 3 140 27 1 A105 27 A106 A107 A108 A109 A110 A111 A112 A113 et al

2 2.1 2 2.1.1 2.1.1 4060 4060 *1 3550 3550 3550 *2 4060 4060 1520 7095 6090 4060 4060 4060 4080 3070 3001500 200400 40200 - - 5002000 15003500 60200 *1 *2 6 2.1.1 1 2 3 2.1.2 1 7 2 3 4 180 5 2 6 3,000K

広報あぐい　2014年1月15日号

442号

untitled

NIHSS score p NIHSS score p149 4 p g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml

NIHSS score14 1 400 1 p149 1 25 20 NIHSS score14 15 10 5 2 p149 4 p151 0 0.8 g ml 0.8 g ml D 1 D NIH NIHSS 14 D 0.8 g ml 1 2 148 149 3 2 3 A B C 4 D 2 A B C A C 1 Ogata T et al J Neurol Sci 272 83 86 2008

fpj

Folia Pharmacol. Jpn. 145 C 天野 学 1), 石川博樹 2) 要約 : genotype C C IFN C HCV A NS A NS / A NS / AHCV in vitro HCV genotype genotype HCV HCV Genotype b C mg mg IL B IFN IFN 1. はじめに C HCV, HCV HCV HCV, C HCV.

Cmax AUCo-+on,l, fns/ml 76.468+ t'/.710 x x n=3 l1) Labroo,R.B.etal. : Drug Metab.Dispos. 1997; 25(9): 1072- r 080 l2) Schneider,E.et al. : Naunln Schmiedebergs Arch.Pharmacol. B0T0X'ror injection -0.09

橡HP用.PDF

1 2 3 ... 1... 2... 2... 3... 4... 12...12...12... 14...14...15...16... 17...17... 17...18...18...20...22... 26... 26 ... 27...27...28 32 1 2 3 8 9 O 1 2 7 C ln 6 O 4 3 C ln m + n = 8 8 9 1 2 7 3 C ln

23 3 11 14 46 9.0 7 10m 40.1m 15,883 2,681 25 4 10 39 40 800 180 24 2425 22 21 24 5 3 21 24 10,899 20,472 13,723 33,007 667 400 79,167 8,620 11,694 10,089 25,131 690 215 56,439 13,614 20,897 15,200 32,213

FARM_2018

12 9.5 3 4 NEW NEW NEW 84028 84029 84030 NEW NEW NEW 84031 84032 84033 5 6 NEW NEW NEW NEW 84034 84035 84036 84037 NEW NEW NEW NEW 84038 84039 84040 84041 7 NEW NEW NEW NEW 42001 42002 42003 42004 8 NEW

tr+? +81, v/.\\5rsa$. 9- O{9iu}rr: 5 {to f.!!l r: g7-1.q' e t,}v otl4x (a!a; t- c!.;, E. *B lrr?itat x^62-a G, ^'A : ef{'af.li8 *t'tt* o>zpdy:r5fcz+',2q,3 {a i^{:t{ttft 6dr;/*X.a t,t!,

1 Q A 82% 89% 88% 82% 88% 82%

-1 - -2 - -3 - -4 - -5 - -6 - -7 - -8 - -9- 44-10 - -11 - - 12 - - 13 - - 14 - - 15 - - 16 - - 17 - - 18 - - 19 - - 20 - - 21 - - 22 - - 23 - - 24 - - 25 - - 26 - - 27 - 372 304-28 - - 29 - - 30 - - 31

1 1 2 2 3 4 5 5 6 7 8 10 9 10 10 10 11 13 14 15 15 16 17 18 19 21 21 22 22 24 28 38 40 41 41 43 45 46 47 47 47 47 48 50 50 50 50 51 52 54 54 55 56 56 57 57 57 58 58 59 59 59 61 61 61 62 62 62 62 63 63

03J_sources.key

Radiation Detection & Measurement (1) (2) (3) (4)1 MeV ( ) 10 9 m 10 7 m 10 10 m < 10 18 m X 10 15 m 10 15 m ......... (isotope)...... (isotone)......... (isobar) 1 1 1 0 1 2 1 2 3 99.985% 0.015% ~0% E

世 tt 波 及 び 巡 由 ilj \~1 似 て,I~; に 則 する ~:.i'l(, 制 作 ぜぷ S~~,~ _x..~ ~しお,lj,:','\.~ ~'.\.~'7 与 ぽーσ 'V~. 他 1lUえぴ 迎 íwj\v{ 作 t~' 干 に 則 する 12 1 彼 淵 作 f\l! 1!U>i び 巡 仰 ~ l~1 似 て 字 に 則 するな J 抜 訓 1f. 他!IUえぴ

,398 4% 017,

6 3 JEL Classification: D4; K39; L86,,., JSPS 34304, 47301.. 1 01301 79 1 7,398 4% 017,390 01 013 1 1 01 011 514 8 1 Novos and Waldman (1984) Johnson (1985) Chen and Png (003) Arai (011) 3 1 4 3 4 5 0

D:/BOOK/MAIN/MAIN.DVI

8 2 F (s) =L f(t) F (s) =L f(t) := Z 0 f()e ;s d (2.2) s s = + j! f(t) (f(0)=0 f(0) _ = 0 d n; f(0)=dt n; =0) L dn f(t) = s n F (s) (2.3) dt n Z t L 0 f()d = F (s) (2.4) s s =s f(t) L _ f(t) Z Z ;s L f(t)

2 3 4 q w e 1

ｌ 能率ということ 園田瓊一 新RI会長と新ガバナーの横額 特集 新年度の方針 Introducing Clem Renouf... Quiet Dynamo from Down Under by Paul Henningham Inite Mankind Serve Io.- g.f tlhnkind h"-, 7, u r F'7- F' H.

Microsoft PowerPoint - masayukiakiyama_20141103.pptx

2 / 7

1 / 7 1.30 1.301.00m 2.00 2.001.00m 1.70 1.701.00m 2.4 2.41.0m 2.0 2.01.0m 1.08 1.20.9m 1.08 1.20.9m 2.5 2.51.0m 2.5 2.51.0m 0.9 1.00.9m 1.44 1.60.9m 2 / 7 ml ml 3 / 7 4 / 7 ) 5 / 7 6 / 7 0798-56-1710

13年度主要施策の成果について

N72 T95 T75 T55 T45 T67 T54 N72 RX82 N40 L93 V83 V73 RX73 N51 S90 S80 D81 D51

N72 T75 S80 D81 N72 T95 T75 T55 T45 T67 T54 N72 RX82 N40 L93 V83 V73 RX73 N51 S90 S80 D81 D51 N72 RX82 L93 S90 S80 S90 S80 N72 RX82 L93 N40 N29 N72 RX82 N72 RX82 N72 RX82 T95 T75 T55 T45 T67 T54 RX73 L93

PII S (96)

C C R ( 1 Rvw C d m d M.F. Pllps *, P.S. Hp I q G U W C M H P C C f R 5 J 1 6 J 1 A C d w m d u w b b m C d m d T b s b s w b d m d s b s C g u T p d l v w b s d m b b v b b d s d A f b s s s T f p s s

untitled

PS3 10% 2-1 2-2 2-3 2 23 2-4 1 2 3 4 2-5 2.3.1 1 24 812 2-6 5 5% : (CVC) 5 2-7 CTZ 24 24 2-8 2.3.2 23 5HT3 12 2-9 2.3.3 12 12 23 710 13 5-FU 2-10 2.3.4 24 10 20 5-FU 2-11 2-12 (CTZ) 5HT3 H1 Achm (CTZ)

2 (1) (2) SCI 2 SCI 2 24 2 12 2

2004 (1) (2) (2) (3) (1) 1 (2) (3) 2 (1) (2) SCI 2 SCI 2 24 2 12 2 100% / 16 2002 2003 http://lin.lin.go.jp/alic/month/dome/1997/nov/chousa.htm (05 612 1315 1618 1922 2329 3039 4049 5059 60 ) =10 b g 1

m/(te) rirrnao!...

tql(er) trlriu... m/(te) rirrnao!... aold'lnruai -db. [nrudnl:6'srbu (rl {fifio.jrr"flu{fisvrbrdrirnr:r.j:vrfrunrufnl1ual}r'rrn!,; v d, YA,v - -61- a v -^-^r n:{yr lo oumo{luusjvraouldnvrruulunl:il:vnjurr?'t}j:n?'t}ja'l}.j'ti0

消防研究所の役割等の変化

橡scb79h16y08.PDF

S C B 05 06 04 10 29 05 1990 05 0.1 90 05 0.2 06 90 05 06 06 04 04 10 1.9 90 12 2.0 13 10 10 18.0 16.0 6.1 1 10 1.7 10 18.5 0.8 03 04 1 04 42.9 10 20.5 10 4.2 0.7 0.2 0.6 01 00 100 97 11 102.5 04 91.5

untitled

2009 7 29-30 1 2 + + = 1 = 1 ( = = 0) 3 Eb (, T ) exp[ C C 2 1 5 /( T )] 1 [ W/(m2μm)] : [ m] T : [K] C 1 = 3.743 10 8 [W m 4 /m 2 ] C 2 = 1.439 10 4 [ m K] 4 E b max max T 2897 m m K = 10 m 5 E E b E